(Total Views: 382)
Posted On: 02/12/2020 12:24:14 PM
Post# of 36567
Merck Says Study Shows Keytruda Helps Improve Progression-Free Survival of Breast Cancer Patients
BY MT Newswires
— 8:18 AM ET 02/12/2020
08:18 AM EST, 02/12/2020 (MT Newswires) -- Merck & Co. (MRK) said Wednesday that a phase 3 clinical trial on Keytruda met one of its dual primary endpoints in the treatment of patients with metastatic triple-negative breast cancer.
The data showed that first-line treatment with Keytruda in combination with chemotherapy showed significant improvement in the progression-free survival of patients compared with chemotherapy alone.
Price: 85.74, Change: +0.49, Percent Change: +0.57
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
BY MT Newswires
— 8:18 AM ET 02/12/2020
08:18 AM EST, 02/12/2020 (MT Newswires) -- Merck & Co. (MRK) said Wednesday that a phase 3 clinical trial on Keytruda met one of its dual primary endpoints in the treatment of patients with metastatic triple-negative breast cancer.
The data showed that first-line treatment with Keytruda in combination with chemotherapy showed significant improvement in the progression-free survival of patients compared with chemotherapy alone.
Price: 85.74, Change: +0.49, Percent Change: +0.57
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
(0)
(0)
